Molecular Targets and Mechanism of Action
Zolpidem is a selective $\omega_1$-benzodiazepine receptor agonist.
To understand its mechanism, recall the binding sites of the receptor complex: classical benzodiazepines bind to a site formed by the $\alpha$ and $\gamma$ subunits. Pharmacological effects depend on the specific $\alpha$ subunit isoform within the receptor:
- $\omega_1$ receptors (containing the $\alpha_1$ subunit): activation produces sedative and amnestic effects.
- $\omega_2$ receptors (containing $\alpha_2$-, $\alpha_3$-, or $\alpha_5$ subunits): activation produces anxiolytic effects.
Unlike benzodiazepines, which act non-selectively on both types, zolpidem binds exclusively to $\omega_1$ receptors.
Pathogenesis of CNS Depression:
- Stimulation of benzodiazepine receptors causes allosteric modulation of GABA receptors.
- Increases the sensitivity of $\text{GABA}_A$ receptors to the neurotransmitter GABA.
- Increases the frequency of chloride channel opening, resulting in a massive influx of $Cl^-$ ions into the cell.
- Neuronal membrane hyperpolarization develops, triggering inhibitory processes.
Note: Zolpidem is not an ion channel blocker (NMDA, sodium, or calcium channels) and does not affect GABA reuptake.
Pharmacological Effects and Impact on Sleep
The primary effect of the drug is hypnotic (intermediate duration, with a $t_{1/2}$ of 2–3 hours). In low doses, zolpidem produces a sedative effect.
Important Distinction from Benzodiazepines: Due to its strict selectivity for $\omega_1$ receptors, zolpidem lacks significant anxiolytic, anticonvulsant, and myorelaxant (skeletal muscle relaxant) properties.
Comparative Impact on Sleep Architecture: Hypnotic drugs disrupt the ratio of rapid eye movement (REM) and non-REM sleep to varying degrees:
- Severe disruption: Barbiturate derivatives (e.g., phenobarbital — a narcotic-type hypnotic).
- Moderate disruption: Classical benzodiazepines (diazepam, nitrazepam).
- Minimal disruption: Z-drugs (zolpidem, zopiclone) and aliphatic compounds (chloral hydrate).
Thus, the key advantage of zolpidem is the preservation of a more physiological sleep architecture.
Adverse Effects and Risks
Adverse effects during therapy may include:
- Neurological disturbances: Daytime somnolence, headache, ataxia.
- Psychiatric disturbances: Nightmares, hallucinations.
Rebound insomnia (a marked worsening of sleep following drug discontinuation) is minimal with zolpidem. However, prolonged use leads to tolerance and carries a high risk of developing substance dependence.
Prescribing Guidelines and Overdose
Due to the risk of dependence, the duration of zolpidem therapy is strictly limited — the course should not exceed 4 weeks.
Specific Antidote: In the event of an overdose involving Z-drugs (zolpidem, zaleplon, zopiclone) or classical benzodiazepines accompanied by drug-induced respiratory depression, flumazenil (Flumazenil) is used. It is a competitive antagonist of benzodiazepine receptors administered via intravenous infusion. (For differential diagnosis: opioid analgesic overdose and $\mu$-receptor depression require different antidotes, such as naloxone or naltrexone).
Prescription Example: Rp.: Tab. Zolpidemi 0,01 D.t.d. N. 10 S. Take 1 tablet (0.01 g) orally at bedtime.